Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
- PMID: 38087280
- PMCID: PMC10717932
- DOI: 10.1186/s12917-023-03789-9
Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
Abstract
Background: Peripheral blood carries a reservoir of mRNAs that regulate cardiac structure and function potential. Although it is well recognized that the typical symptoms of Myxomatous Mitral Valve Disease (MMVD) stage B2 are long-standing hemodynamic disorder and cardiac structure remodeling caused by mitral regurgitation, the transcriptomic alterations in blood from such dogs are not understood.
Results: In the present study, comparative high-throughput transcriptomic profiling of blood was performed from normal control (NC) and naturally-occurring MMVD stage B2 (MMVD) dogs. Using Weighted Gene Co-expression Network Analyses (WGCNA), Gene Ontology (GO), and Kyoto Encyclopedia of Gene and Genomes (KEGG), we identified that the turquoise module was the most highly correlated with echocardiographic features and found 64 differentially expressed genes (DEGs) that were significantly enriched in platelet activation related pathways. Therefore, from the turquoise module, we selected five DEGs (MDM2, ROCK1, RIPK1, SNAP23, and ARHGAP35) that, according to real-time qPCR, exhibited significant enrichment in platelet activation related pathways for validation. The results showed that the blood transcriptional abundance of MDM2, ROCK1, RIPK1, and SNAP23 differed significantly (P < 0.01) between NC and MMVD dogs. On the other hand, Correlation Analysis revealed that MDM2, ROCK1, RIPK1, and SNAP23 genes negatively regulated the heart structure parameters, and followed the same trend as observed in WGCNA.
Conclusion: We screened four platelet activation related genes, MDM2, ROCK1, RIPK1, and SNAP23, which may be considered as the candidate biomarkers for the diagnosis of MMVD stage B2. These findings provided new insights into MMVD pathogenesis.
Keywords: Biomarkers; Dog; MDM2; Myxomatous mitral valve; Transcriptomic.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig6_HTML.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10717932/bin/12917_2023_3789_Fig7_HTML.gif)
Similar articles
-
RNA sequencing provides novel insights into the pathogenesis of naturally occurring myxomatous mitral valve disease stage B1 in beagle dogs.PLoS One. 2024 May 16;19(5):e0300813. doi: 10.1371/journal.pone.0300813. eCollection 2024. PLoS One. 2024. PMID: 38753730 Free PMC article.
-
Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.J Proteomics. 2023 Jun 30;282:104924. doi: 10.1016/j.jprot.2023.104924. Epub 2023 May 3. J Proteomics. 2023. PMID: 37146676
-
Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.BMC Vet Res. 2019 Nov 27;15(1):425. doi: 10.1186/s12917-019-2169-1. BMC Vet Res. 2019. PMID: 31775756 Free PMC article.
-
Current use of real-time three-dimensional transthoracic echocardiography in animals.J Vet Cardiol. 2024 Feb;51:97-104. doi: 10.1016/j.jvc.2023.11.009. Epub 2023 Nov 13. J Vet Cardiol. 2024. PMID: 38118235 Review.
-
Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.Cardiovasc Pathol. 2020 May-Jun;46:107196. doi: 10.1016/j.carpath.2019.107196. Epub 2020 Jan 7. Cardiovasc Pathol. 2020. PMID: 32006823 Free PMC article. Review.
Cited by
-
RNA sequencing provides novel insights into the pathogenesis of naturally occurring myxomatous mitral valve disease stage B1 in beagle dogs.PLoS One. 2024 May 16;19(5):e0300813. doi: 10.1371/journal.pone.0300813. eCollection 2024. PLoS One. 2024. PMID: 38753730 Free PMC article.
References
-
- Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: the BEnazepril Spironolactone STudy (BESST) J Vet Intern Med. 2021;35(4):1673–1687. doi: 10.1111/jvim.16155. - DOI - PMC - PubMed
-
- Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135. doi: 10.1111/j.1939-1676.2008.0150.x. - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous